GlassScriptPhysician profile
Swati Jain
NPI 1104848647
$546.31
in general payments reported to CMS, 2019-2025
16 companies · $28.20 in 2025
The $28.20 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $134 · 2021: $114 · 2022: $79.74 · 2023: $38.35 · 2025: $28.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.89 | 2019-2021 | |
| Therapeuticsmd, INC. | $66.39 | 2019-2022 | |
| Hologic Sales and Service, LLC | $62.91 | 2019 | |
| Pfizer INC. | $57.63 | 2022-2023 | |
| Agile Therapeutics, INC. | $33.93 | 2021 | |
| Exeltis, USA INC. | $28.20 | 2021 | |
| Medline Industries LP | $27.55 | 2022 | |
| Shield Therapeutics INC | $19.66 | 2023 | Accrufer |
| Biogen, INC. | $18.25 | 2025 | Zurzuvae |
| Opko Pharmaceuticals, LLC | $17.09 | 2020 | |
| Fresenius USA Marketing, INC. | $14.67 | 2021 | |
| Boston Scientific Corporation | $14.37 | 2019 | |
| Vifor Pharma, INC. | $14.01 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.83 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $9.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.